GlassScriptPhysician profile
Scott J Ratner
NPI 1932143997
$9,579.18
in general payments reported to CMS, 2019-2025
30 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $777 · 2021: $1,865 · 2022: $1,085 · 2023: $1,441 · 2024: $1,695 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,656.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,070.42 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $1,024.30 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $877.22 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $764.35 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Abbott Laboratories | $660.86 | 2019-2024 | Aveir, Assurity |
| Pfizer INC. | $647.23 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $625.00 | 2021 | |
| Amarin Pharma, INC. | $585.35 | 2019-2022 | |
| Novo Nordisk INC | $514.67 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $440.45 | 2019-2025 | Lokelma, Farxiga |
| Scpharmaceuticals INC. | $261.93 | 2023-2025 | |
| Esperion Therapeutics, INC. | $258.94 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $248.01 | 2020-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $226.18 | 2021-2022 | |
| Medtronic Vascular, INC. | $183.38 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $183.15 | 2023-2024 | Inpefa |
| Abiomed | $157.93 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.47 | 2025 | |
| Amgen INC. | $139.87 | 2019 | |
| Bridgebio Pharma, INC. | $94.52 | 2025 | Attruby |
| Heartflow, INC. | $77.64 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.46 | 2023-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $66.12 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $62.93 | 2025 | Amvuttra |
| Sanofi Pasteur INC. | $62.40 | 2019-2022 | |
| Boston Scientific Corporation | $51.25 | 2021-2025 | Watchman Flx |
| Kestra Medical Technology Services, INC. | $26.73 | 2023 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.22 | 2019 | |
| Lilly USA, LLC | $14.44 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ratner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.